A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission-Reference-Cited by-同舟云学术

A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission

Published:2017 Issue:2 Volume:57 Page:79-81
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Sekiguchi Yasunobu¹,Wakabayashi Mutsumi¹,Takizawa Haruko¹,Sugimoto Keiji¹,Tomita Shigeki²,Izumi Hiroshi²,Nakamura Noriko³,Sawada Tomohiro³,Ohta Yasunori⁴,Komatsu Norio⁵,Noguchi Masaaki¹

Affiliation:

1. Department of Hematology, Juntendo University Urayasu Hospital

2. Department of Pathology, Juntendo University Urayasu Hospital

3. Department of Clinical Laboratory, Juntendo University Urayasu Hospital

4. Department of Pathology, Research Hospital, Institute of Medical Science, the University of Tokyo

5. Department of Hematology, Juntendo University Hospital

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/57/2/57_17022/_pdf

Reference11 articles.

1. 1 Kath R, Blumenstengel K, Fricke HJ, Höffken K: Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127(1):48-54, 2001

2. 2 Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD: Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 116(1):106-14, 2010

3. 3 Special drug use results survey of Treakisym^® for Injection 100 mg (all-case surveillance) ― Survey of safety and efficacy in relapsed or refractory low-grade B-cell non-Hodgkin lymphoma and mantle cell lymphoma (all-case surveillance) ― Report of survey results. Eisai Co., Ltd. http://treakisym.com/pdf/pms3.pdf#search

4. 4 Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, Matsumoto Y, Shimizu D, Ogawa Y, Ohmachi K, Yokoyama H, Tobinai K; Japanese Bendamustine Lymphoma Study Group: Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9): 2054-8, 2010

5. 5 Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP: Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol 75(6):1143-54, 2015